Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Total body irradiation (TBI) can induce lethal myelosuppression, due to the sensitivity of proliferating hematopoietic stem/progenitor cells (HSPCs) to ionizing radiation (IR). No effective therapy exists to mitigate the hematologic toxicities of TBI. Here, using selective and structurally distinct small molecule inhibitors of cyclin-dependent kinase 4 (CDK4) and CDK6, we have demonstrated that selective cellular quiescence increases radioresistance of human cell lines in vitro and mice in vivo. Cell lines dependent on CDK4/6 were resistant to IR and other DNA-damaging agents when treated with CDK4/6 inhibitors. In contrast, CDK4/6 inhibitors did not protect cell lines that proliferated independently of CDK4/6 activity. Treatment of wild-type mice with CDK4/6 inhibitors induced reversible pharmacological quiescence (PQ) of early HSPCs but not most other cycling cells in the bone marrow or other tissues. Selective PQ of HSPCs decreased the hematopoietic toxicity of TBI, even when the CDK4/6 inhibitor was administered several hours after TBI. Moreover, PQ at the time of administration of therapeutic IR to mice harboring autochthonous cancers reduced treatment toxicity without compromising the therapeutic tumor response. These results demonstrate an effective method to mitigate the hematopoietic toxicity of IR in mammals, which may be potentially useful after radiological disaster or as an adjuvant to anticancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies revealed that CDK4/6 inhibitors protect both cancer cells and normal hematopoietic cells from cytotoxicity induced by IR and DNA damaging agents (125)”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [125]
Experimental — accuracy not yet measuredIn the citing paper
“p21 upregulation actually protected HSCs against IR by limiting IR-induced DNA damage and p53 activation and by promoting HSC cell cycle entry and self-renewing expansion, suggesting that p21 and p16 may have opposite effects on IR-induced HSC senescence.46-48”
From Total body irradiation causes long-term mouse BM injury via induction of HSC premature senescence in an Ink4a- and Arf-independent manner (2014) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clonogenic assay of cells in vitro
Franken, N. A. P., Rodermond, H. M., Stap, J., Haveman, J., & van Bree, C. (2006) · Nature Protocols · doi:10.1038/nprot.2006.339 · Cited by 4,188
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
Kiel, M. J., Yilmaz, Ö. H., Iwashita, T., Yilmaz, O. H., Terhorst, C., & Morrison, S. J. (2005) · Cell · doi:10.1016/j.cell.2005.05.026 · Cited by 3,168
The comet assay: a method to measure DNA damage in individual cells
Olive, P. L., & Banáth, J. P. (2006) · Nature Protocols · doi:10.1038/nprot.2006.5 · Cited by 1,835
Dulić, V., Kaufmann, W. K., Wilson, S. J., Tisty, T. D., Lees, E., Harper, J. W., Elledge, S. J., & Reed, S. I. (1994) · Cell · doi:10.1016/0092-8674(94)90379-4 · Cited by 1,465 · cited 1×
“Prior work in mice has shown that p21CIP, a potent CDK inhibitor and critical mediator of the p53-mediated DNA damage response (29, 30), plays an important role in regulating HSPC quiescence after DNA damage (31).”
A Restriction Point for Control of Normal Animal Cell Proliferation
Pardee, A. B. (1974) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.71.4.1286 · Cited by 1,415
Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
Hematopoietic Stem Cell Quiescence Maintained by p21 cip1/waf1
Cheng, T., Rodrigues, N., Shen, H., Yang, Y.-G., Dombkowski, D., Sykes, M., & Scadden, D. T. (2000) · Science · doi:10.1126/science.287.5459.1804 · Cited by 1,339
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 2×
“PD0332991 (13, 14) was provided by Pfizer Inc.”
BackgroundMethodDi Leonardo, A., Linke, S. P., Clarkin, K., & Wahl, G. M. (1994) · Genes & Development · doi:10.1101/gad.8.21.2540 · Cited by 1,215
Living with or without cyclins and cyclin-dependent kinases
Sherr, C. J., & Roberts, J. M. (2004) · Genes & Development · doi:10.1101/gad.1256504 · Cited by 1,089
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
Single-strand break repair and genetic disease
Caldecott, K. W. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2380 · Cited by 1,034
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793 · cited 2×
“For example, murine embryos lacking both CDK4 and CDK6 or all the D-type cyclins demonstrate normal proliferation in many tissues but succumb late in development, due to a lack of fetal hematopoietic stem/progenitor cells (HSPCs) (9, 10).”
Elkind, M. M., & Sutton, H. (2012) · Radiation Research · doi:10.1667/rrav02.1 · Cited by 706
An Agonist of Toll-Like Receptor 5 Has Radioprotective Activity in Mouse and Primate Models
Burdelya, L. G., Krivokrysenko, V. I., Tallant, T. C., Strom, E., Gleiberman, A. S., Gupta, D., Kurnasov, O. V., Fort, F. L., Osterman, A. L., DiDonato, J. A., et al. (2008) · Science · doi:10.1126/science.1154986 · Cited by 705
Mouse development and cell proliferation in the absence of D-cyclins
Kozar, K., Ciemerych, M. A., Rebel, V. I., Shigematsu, H., Zagozdzon, A., Sicinska, E., Geng, Y., Yu, Q., Bhattacharya, S., Bronson, R. T., et al. (2004) · Cell · doi:10.1016/j.cell.2004.07.025 · Cited by 647 · cited 2×
“For example, murine embryos lacking both CDK4 and CDK6 or all the D-type cyclins demonstrate normal proliferation in many tissues but succumb late in development, due to a lack of fetal hematopoietic stem/progenitor cells (HSPCs) (9, 10).”
BackgroundPassegué, E., Wagers, A. J., Giuriato, S., Anderson, W. C., & Weissman, I. L. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050967 · Cited by 646 · cited 2×
“Proliferation of murine HSCs (Lin– Kit+Sca1+CD48–CD150+), as measured by Ki67 expression and incorporation of BrdU over 24 hours (Figure 3), was comparable to prior estimates (22, 23).”
ResultElkind, M. M., & Sutton, H. (1960) · Radiation Research · doi:10.2307/3570945 · Cited by 550
X-Ray Sensitivity during the Cell Generation Cycle of Cultured Chinese Hamster Cells
Sinclair, W. K., & Morton, R. A. (1966) · Radiation Research · doi:10.2307/3572025 · Cited by 547
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049354h · Cited by 513 · cited 2×
“PD0332991 (13, 14) was provided by Pfizer Inc.”
BackgroundMethodHuman CtIP Mediates Cell Cycle Control of DNA End Resection and Double Strand Break Repair
Huertas, P., & Jackson, S. P. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808906200 · Cited by 511
X-Ray Damage and Recovery in Mammalian Cells in Culture
ELKIND, M. M., & SUTTON, H. (1959) · Nature · doi:10.1038/1841293a0 · Cited by 501
DNA damage checkpoint control in cells exposed to ionizing radiation
Iliakis, G., Wang, Y., Guan, J., & Wang, H. (2003) · Oncogene · doi:10.1038/sj.onc.1206682 · Cited by 476
Self-citationHaematopoietic stem cells do not asymmetrically segregate chromosomes or retain BrdU
Kiel, M. J., He, S., Ashkenazi, R., Gentry, S. N., Teta, M., Kushner, J. A., Jackson, T. L., & Morrison, S. J. (2007) · Nature · doi:10.1038/nature06115 · Cited by 417 · cited 1×
“Proliferation of murine HSCs (Lin– Kit+Sca1+CD48–CD150+), as measured by Ki67 expression and incorporation of BrdU over 24 hours (Figure 3), was comparable to prior estimates (22, 23).”
ResultThe Restriction Point of the Cell Cycle
Blagosklonny, M. V., & Pardee, A. B. (2002) · Cell Cycle · doi:10.4161/cc.1.2.108 · Cited by 412
Cooperative effects of INK4a and ras in melanoma susceptibility in vivo
Chin, L., Pomerantz, J., Polsky, D., Jacobson, M., Cohen, C., Cordon-Cardo, C., Horner, J. W., & DePinho, R. A. (1997) · Genes & Development · doi:10.1101/gad.11.21.2822 · Cited by 402
Growth Inhibition With Reversible Cell Cycle Arrest of Carcinoma Cells by Flavone L86-8275
Kaur, G., Stetler-Stevenson, M., Sebers, S., Worland, P., Sedlacek, H., Myers, C., Czech, J., Naik, R., & Sausville, E. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.22.1736 · Cited by 346
F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage
Santra, M. K., Wajapeyee, N., & Green, M. R. (2009) · Nature · doi:10.1038/nature08011 · Cited by 284
Hershman, D., Neugut, A. I., Jacobson, J. S., Wang, J., Tsai, W.-Y., McBride, R., Bennett, C. L., & Grann, V. R. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djk028 · Cited by 279
Radiation response of mammalian cells grown in culture
Mohler, W. C., & Elkind, M. M. (1963) · Experimental Cell Research · doi:10.1016/0014-4827(63)90325-2 · Cited by 276
Induction of DNA synthesis and apoptosis are separable functions of E2F-1.
Phillips, A. C., Bates, S., Ryan, K. M., Helin, K., & Vousden, K. H. (1997) · Genes & Development · doi:10.1101/gad.11.14.1853 · Cited by 259
History and development of radiation-protective agents
Weiss, J. F., & Landauer, M. R. (2009) · International Journal of Radiation Biology · doi:10.1080/09553000902985144 · Cited by 258
X-Ray Sensitivity and DNA Synthesis in Synchronous Populations of HeLa Cells
Terasima, T., & Tolmach, L. J. (1963) · Science · doi:10.1126/science.140.3566.490 · Cited by 248
Tip60: Connecting chromatin to DNA damage signaling
Sun, Y., Jiang, X., & Price, B. D. (2010) · Cell Cycle · doi:10.4161/cc.9.5.10931 · Cited by 230
Meng, A., Wang, Y., Zant, G. E. V., & Zhou, D. (2003) · PubMed · Cited by 222
Self-citationLITTLE, J. B. (1969) · Nature · doi:10.1038/224804a0 · Cited by 207
Na Nakorn, T., Traver, D., Weissman, I. L., & Akashi, K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15272 · Cited by 189
Wang, Y. A., Elson, A., & Leder, P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.26.14590 · Cited by 170
Self-citationX-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells.
Sinclair, W. K., & Morton, R. A. (1966) · PubMed · Cited by 167
Na Nakorn, T., Traver, D., Weissman, I. L., & Akashi, K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215272 · Cited by 167
Hirschmann-Jax, C., Foster, A. E., Wulf, G. G., Goodell, M. A., & Brenner, M. K. (2004) · Cell Cycle · doi:10.4161/cc.4.2.1406 · Cited by 157
Le Deley, M.-C., Suzan, F., Cutuli, B., Delaloge, S., Shamsaldin, A., Linassier, C., Clisant, S., de Vathaire, F., Fenaux, P., & Hill, C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9048 · Cited by 150
Cdk1 Participates in BRCA1-Dependent S Phase Checkpoint Control in Response to DNA Damage
Johnson, N., Cai, D., Kennedy, R. D., Pathania, S., Arora, M., Li, Y.-C., D'Andrea, A. D., Parvin, J. D., & Shapiro, G. I. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.06.036 · Cited by 138
Hérodin, F., Bourin, P., Mayol, J.-F., Lataillade, J.-J., & Drouet, M. (2003) · Blood · doi:10.1182/blood-2002-06-1634 · Cited by 138
Chu, X., DePinto, W., Bartkovitz, D., So, S., Vu, B. T., Packman, K. E., Lukacs, C., Ding, Q., Jiang, N., Wang, K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0606138 · Cited by 128
Deans, A. J., Khanna, K. K., McNees, C. J., Mercurio, C., Heierhorst, J., & McArthur, G. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3945 · Cited by 125
Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo
Sharpless, N. E., Kannan, K., Xu, J., Bosenberg, M., & Chin, L. (2003) · Oncogene · doi:10.1038/sj.onc.1206809 · Cited by 116
Self-citationRoots, R., Kraft, G., & Gosschalk, E. (1985) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(85)90147-6 · Cited by 97
Zhu, G., Conner, S. E., Zhou, X., Shih, C., Li, T., Anderson, B. D., Brooks, H. B., Campbell, R. M., Considine, E., Dempsey, J. A., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0256169 · Cited by 96
Uckun, F., Souza, L., Waddick, K., Wick, M., & Song, C. (1990) · Blood · doi:10.1182/blood.v75.3.638.638 · Cited by 94
Treatment of growing teratoma syndrome
Vaughn, D. J., Flaherty, K., Lal, P., Gallagher, M., O'Dwyer, P., Wilner, K., Chen, I., & Schwartz, G. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0808558 · Cited by 82
Shields, J. M., Thomas, N. E., Cregger, M., Berger, A. J., Leslie, M., Torrice, C., Hao, H., Penland, S., Arbiser, J., Scott, G., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3311 · Cited by 81
Self-citationTyagi, S., & Herr, W. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.258 · Cited by 77
DNA interstrand cross-links induced by ionizing radiation: An unsung lesion
Dextraze, M.-E., Gantchev, T. G., Girouard, S., & Hunting, D. J. (2010) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2009.12.007 · Cited by 71
Chen, X., Lowe, M., Herliczek, T., Hall, M. J., Danes, C., Lawrence, D. A., & Keyomarsi, K. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.24.1999 · Cited by 66
Ramsey, M. R., Krishnamurthy, J., Pei, X.-H., Torrice, C., Lin, W., Carrasco, D. R., Ligon, K. L., Xiong, Y., & Sharpless, N. E. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3437 · Cited by 61
Self-citationCdk Inhibition in Human Cells Compromises Chk1 Function and Activates a DNA Damage Response
Maude, S. L., & Enders, G. H. (2005) · Cancer Research · doi:10.1158/0008-5472.780.65.3 · Cited by 59
Revisiting the “Cdk-Centric” View of the Mammalian Cell Cycle
Malumbres, M. (2004) · Cell Cycle · doi:10.4161/cc.4.2.1410 · Cited by 50
The importance of G1/S-border and mitosis in the fixation of potentially lethal damage
Iliakis, G. E., & N�sse, M. (1983) · Radiation and Environmental Biophysics · doi:10.1007/bf01323709 · Cited by 26
Mosesso, P., Palitti, F., Pepe, G., Piñero, J., Bellacima, R., Ahnström, G., & Natarajan, A. T. (2010) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2010.03.005 · Cited by 22
Protective Effect of a Colchicine Derivative in Mice Exposed to X-Radiation
Smith, W. W. (1958) · Science · doi:10.1126/science.127.3294.340 · Cited by 22
A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991
O'Dwyer, P. J., LoRusso, P. M., DeMichele, A., Gupta, V., Barbi, A., Dials, H. J., Chen, I., Courtney, R., Wilner, K. D., & Schwartz, G. K. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3550 · Cited by 20
Radioprotection by Mitotic Inhibitors and Mercaptoethylamine
Rothe, W., & Grenan, M. M. (1961) · Science · doi:10.1126/science.133.3456.888 · Cited by 17
Cyclin-dependent kinase inhibitors: a survey of the recent patent literature
Pevarello, P., & Villa, M. (2005) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.15.6.675 · Cited by 14
Hsp90 inhibitors: A potential treatment for latent EBV infection?
Sun, X., & Kenney, S. C. (2010) · Cell Cycle · doi:10.4161/cc.9.9.11594 · Cited by 13
Cited by
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
“Although it has been suggested that CDK4/CDK6 inhibitors could be used to induce reversible quiescence, thereby protecting normal cells from radiation-induced toxicit”
BackgroundTargeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Hematopoietic stem cell niche maintenance during homeostasis and regeneration
Mendelson, A., & Frenette, P. S. (2014) · Nature Medicine · doi:10.1038/nm.3647 · Cited by 792
Targeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 531
Metadata
- Authors
- Johnson, S. M., Torrice, C. D., Bell, J. F., Monahan, K. B., Jiang, Q., Wang, Y., Ramsey, M. R., Jin, J., Wong, K.-K., Su, L., Zhou, D., & Sharpless, N. E.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Medical University of South Carolina (US)
- Harvard University (US)
- Corresponding author
- Sharpless, Norman E.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2010-07-01
- Volume
- 120
- Issue
- 7
- Pages
- 2528-2536
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2898594
- OpenAlex
- W1967829518
- Cited by
- 168
- References
- 66
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 6 · 2023: 4 · 2022: 8 · 2021: 12 · 2020: 10 · 2019: 10 · 2018: 10 · 2017: 8 · 2016: 15 · 2015: 16 · 2014: 14 · 2013: 14 · 2012: 7
- FWCI
- 10.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health (5r01ag024379-15)
- National Institute on Aging (R01-AG024379, F30AG034806)
- National Cancer Institute (R01CA122023, R01CA122794, R01CA086860)
- National Institute of General Medical Sciences (GM008581, T32GM008719, T32GM008581)
- National Institute of Allergy and Infectious Diseases (R01AI080421, R01AI077454, R01AI080432)
- National Institute of Environmental Health Sciences (P30ES010126)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Keywords
- CDK4/6 inhibitors, total body irradiation, hematopoietic stem and progenitor cells, quiescent cells, radioresistance (biology), myelosuppression, ionizing radiation, DNA-damaging agents, bone marrow, autochthonous tumors, cancer therapy
- MeSH terms
- Animals, Antineoplastic Agents, Cell Cycle, Cell Line, Hematopoietic Stem Cells, Mice, Inbred C3H, Mice, Inbred C57BL, Radiation, Mice, Knockout, Cyclin-Dependent Kinase Inhibitor p18, Cyclin-Dependent Kinase 4, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.